Molecular process of glucose uptake and glycogen storage due to hamamelitannin via insulin signalling cascade in glucose metabolism

Mol Biol Rep. 2020 Sep;47(9):6727-6740. doi: 10.1007/s11033-020-05728-5. Epub 2020 Aug 18.

Abstract

Understanding the mechanism by which the exogenous biomolecule modulates the GLUT-4 signalling cascade along with the information on glucose metabolism is essential for finding solutions to increasing cases of diabetes and metabolic disease. This study aimed at investigating the effect of hamamelitannin on glycogen synthesis in an insulin resistance model using L6 myotubes. Glucose uptake was determined using 2-deoxy-D-[1-3H] glucose and glycogen synthesis were also estimated in L6 myotubes. The expression levels of key genes and proteins involved in the insulin-signaling pathway were determined using real-time PCR and western blot techniques. The cells treated with various concentrations of hamamelitannin (20 µM to 100 µM) for 24 h showed that, the exposure of hamamelitannin was not cytotoxic to L6 myotubes. Further the 2-deoxy-D-[1-3H] glucose uptake assay was carried out in the presence of wortmannin and Genistein inhibitor for studying the GLUT-4 dependent cell surface recruitment. Hamamelitannin exhibited anti-diabetic activity by displaying a significant increase in glucose uptake (125.1%) and glycogen storage (8.7 mM) in a dose-dependent manner. The optimum concentration evincing maximum activity was found to be 100 µm. In addition, the expression of key genes and proteins involved in the insulin signaling pathway was studied to be upregulated by hamamelitannin treatment. Western blot analysis confirmed the translocation of GLUT-4 protein from an intracellular pool to the plasma membrane. Therefore, it can be conceived that hamamelitannin exhibited an insulinomimetic effect by enhancing the glucose uptake and its further conversion into glycogen by regulating glucose metabolism.

Keywords: Glycogen synthesis; Hamamelitannin; Insulin signalling; Molecular process; Type II diabetes mellitus.

MeSH terms

  • Animals
  • Biological Transport / drug effects
  • Carbohydrate Metabolism / drug effects
  • Cell Survival / drug effects
  • Diabetes Mellitus, Type 2 / drug therapy
  • Gallic Acid / analogs & derivatives*
  • Gallic Acid / metabolism
  • Gallic Acid / pharmacology
  • Genistein / pharmacology
  • Glucose / metabolism*
  • Glucose Transporter Type 4 / genetics
  • Glucose Transporter Type 4 / metabolism*
  • Glycogen / metabolism*
  • Glycogen Synthase Kinase 3 beta / genetics
  • Glycogen Synthase Kinase 3 beta / metabolism
  • Hexoses / metabolism
  • Hexoses / pharmacology*
  • Insulin / metabolism*
  • Insulin / pharmacology
  • Insulin Antagonists / pharmacology
  • Insulin Resistance
  • Muscle Fibers, Skeletal / drug effects*
  • Muscle Fibers, Skeletal / metabolism*
  • Myoblasts / drug effects*
  • Myoblasts / metabolism
  • Phosphatidylinositol 3-Kinases / genetics
  • Phosphatidylinositol 3-Kinases / metabolism
  • Protein Kinase Inhibitors / pharmacology
  • Protein-Tyrosine Kinases / genetics
  • Protein-Tyrosine Kinases / metabolism
  • Rats
  • Signal Transduction / drug effects
  • Wortmannin / pharmacology

Substances

  • Glucose Transporter Type 4
  • Hexoses
  • Insulin
  • Insulin Antagonists
  • Protein Kinase Inhibitors
  • Slc2a4 protein, rat
  • Gallic Acid
  • Glycogen
  • Genistein
  • insulin receptor tyrosine kinase
  • Protein-Tyrosine Kinases
  • Glycogen Synthase Kinase 3 beta
  • Glucose
  • Wortmannin
  • hamamelitannin